An Observational Study of Patients With Philadelphia Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

简要总结

主要结局

次要结局

• Incidence of selected adverse events including cytokine release syndrome, neurologic events, any events resulting in hospitalizations, and other serious adverse events.(86 Months)
• RFS from time remission achieved with salvage treatment(86 Months)
• MRD status within 12 weeks of initiation of salvage treatment(12 Weeks)
• Overall survival from the time of initiation of salvage treatment(86 Months)
• Receipt of allogeneic stem cell transplantation following salvage treatment(86 Months)
• Best response to salvage treatment (chemotherapy or blinatumomab) within 8 weeks and within 12 weeks of initiation of salvage treatment.(12 Weeks)